

## INFORMAZIONI PERSONALI

## Federico Cappuzzo

 [federico.cappuzzo@auslromagna.it](mailto:federico.cappuzzo@auslromagna.it)

Sesso maschile | Data di nascita | Nazionalità Italiana

ESPERIENZA  
PROFESSIONALE

---

Da Gennaio 2017- in corso	<b>Direttore Dipartimento Onco-ematologico Ausl Romagna</b> AUSL della Romagna Via de Gasperi,8 Ravenna
Da Aprile 2016- in corso	<b>Direttore U.O.C Oncologia Ravenna</b> AUSL della Romagna Ospedale S. Maria delle Croci
Maggio 2014 - Luglio 2016	<b>Presidente Fondazione di Ricerca Traslazionale (FoRT)</b> Fondazione FoRT Roma
Gennaio 2010 - Aprile 2016	<b>Direttore Oncologia medica</b> USL Toscana Ospedale Civile di Livorno
Dicembre 2010 - Aprile 2016	<b>Direttore del Dipartimento di Oncologia</b> USL Toscana Ospedale Civile di Livorno
Novembre 2006 - Gennaio 2010	<b>Dirigente Medico di primo livello in Oncologia medica</b> Istituto Clinico Humanitas IRCCS Rozzano (Milano)
Gennaio 2004 - Novembre 2004	<b>Visiting associate Professor</b> Dipartimento di oncologia medica- Università del Colorado, Denver (USA)
Novembre 2000 - Novembre 2006	<b>Dirigente Medico di primo livello in Oncologia Medica</b> Ospedale Bellaria Bologna
Aprile 2000 – Settembre 2000	<b>Borsa di studio in oncologia toracica</b> Medical University of South Carolina Charleston (USA)
Ottobre 1999-Marzo 2000	<b>Consulente Medico</b> Ospedale Bellaria

Bologna

Agosto 1997 – Settembre 1999 **Borsa di Studio ESMO (European Society for Clinical oncology) \_  
Terapia genica del carcinoma al polmone**  
Institut Gustave Roussy in Villejuif (Paris)

Novembre 1996 – Giugno 1997 **Borsa di Studio in Oncologia Medica**  
Istituto Nazionale Tumori, Milano

Novembre 1992 – Novembre 1996 **Iscritto al programma di specializzazione in Oncologia Medica**  
Istituto Nazionale Tumori, Milano

Ottobre 1991 – Novembre 1992 **Tirocinio all'Azienda Ospedaliera Universitaria di Palermo**  
A.O.U di Palermo

ISTRUZIONE E FORMAZIONE

Settembre 1997 **Certificazione ESMO in Oncologia Medica**  
European Society for Clinical Oncology

Novembre 1996 **Laurea Specialistica in Oncologia Medica** Summa cum laude  
Università di Milano

Novembre 1992 **Laurea in Medicina e chirurgia** Summa cum laude  
Università di Palermo

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	Ottimo	Ottima	Ottima	Ottima	Ottima
Francese	Ottimo	Ottima	Ottima	Ottima	Buona

ULTERIORI INFORMAZIONI

Dal 1994 Membro dell'Associazione italiana di Oncologia Medica (AIOM)

Dal 1996 Membro dell'European Society of Medical oncology (ESMO)

Dal 2001 Membro dell'American Society Clinical Oncology (ASCO)

Dal 2004 Membro dell' International Association for the Study of Lung Cancer (IASLC)

Dal 2006 Membro del board editoriale della rivista Lung Cancer

Da gennaio 1997 registrato al General medical Council (GMC)

Dal 2013 al 2017 Chairman del programma educativo dell'IASLC

Giugno 2016: GCP training

Ottobre 2016: BLS – Basic Life Support – Defibrillation

Novembre 2016: Conseguimento requisiti richiesti dalla Determina AIFA sulla conduzione di studi di fase I presso le Unità Cliniche dell'AUSL della Romagna

Dicembre 2016: ALS – Advanced Life Support

**Pubblicazioni** Vedi allegato A

**Brevetti**

**2008:** Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients

**2010:** MYC detection as predictor for sensitivity to anti-EGFR therapies in non-small-cell lung cancer

**Grant**

**2006-2008:** grant da AIRC (Associazione Italiana Ricerca sul Cancro) per “terapie target nei tumori”

2009-2011: Grant da AIRC per “meccanismi di resistenza alle terapie target in carcinomi polmonari e del colon retto”

**2012-2014:** grant da AIRC per “Test di sensibilità delle cellule staminali tumorali in pazienti con tumore al polmone non a piccole cellule metastatico”

**2012-2013:** grant da Istituto Toscano dei Tumori per “espressione di MIR128 e LET7 ed efficacia delle terapie anti-EGFR nel tumore al polmone non a piccole cellule metastatico con mutazioni EGFR o KRAS.

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali.

## ALLEGATO A

## Pubblicazioni MEDLINE

ORCID: 0000-0002-6295-6767

Pubmed:

Total publications: 185

First/last author: 96

Google scholar: (<https://scholar.google.it/citations?user=BcSTvHYAAAAJ&hl=it>)

Total Number of citations: 18624

Total Number of citations since 2011: 12896

H index: 59

H index since 2011: 46

i10-index: 135

i10-index since 2011: 114

1. Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. Mazza V., Cappuzzo F. J Thoracic Dis. 2016 Oct; 8(10): E1348-E1350 PMID:27867624
2. Crizotinib: from discovery to accelerated development to front-line treatment. Blackhall F., Cappuzzo F. Ann Oncol. 2016 Sep; 27 Suppl3: iii35-iii41 doi:10.1093/annonc/mdw304. Review PMID: 27573754
3. Targeting MET in Lung Cancer: Will Expectations Finally Be MET? Drilon A, **Cappuzzo F**, Ignatius Ou SH, Camidge DR J Thoracic Oncol. 2016 Oc; t 26: S1556-0864(16)31179-0 doi: 10.1016/j.jtho.2016.10.014. [Epub ahead of print] Review PMID: 27794501
4. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. **Cappuzzo F**, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F. Lung Cancer 2016 Sep; 99: 31.37. doi: <http://dx.doi.org/10.1016/j.lungcan.2016.06.008>
5. EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung patients: 2,387 cases from a single center. Giannini R, Lupi C, Sensi E, Ali G, Proietti A, Boldrini L, Servadio A, Giordano M, Macerola E, Bruno R, Borrelli N, Chella A, Melfi F, Lucchi M, Ribechini A, Vasile E, **Cappuzzo F**, Mussi A, Fontanini G. Oncol Rep. 2016 Aug;36(2):1166-72. doi: 10.3892/or.2016.4874. Epub 2016 Jun 14. PMID: 27373829
6. Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Romanidou O, Landi L, **Cappuzzo F**, Califano R Ther Adv Med Oncol. 2016 May;8(3):176-87. doi: 10.1177/1758834016631531. Epub 2016 Feb 16. Review. PMID: 27239236 Free PMC Article
7. cMET exon 14 skipping: from the structure to the clinic Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, **Cappuzzo F**, Hirsch FR, Rolfo C. J Thorac Oncol. 2016 May 17. pii: S1556-0864(16)30454-3. doi: 10.1016/j.jtho.2016.05.005.

- [Epub ahead of print] Review.  
PMID: 27223456
8. 137O: Nivolumab in patients (PTS) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses.  
Lena H, Rizvi NA, Wolf J, **Cappuzzo F**, Zalcman G, Baas P, Mazieres J, Farsaci B, Blackwood-Chirchir MA, Ramalingam S  
J Thorac Oncol. 2016 Apr;11(4 Suppl):S115-6. doi: 10.1016/S1556-0864(16)30247-7. Epub 2016 Apr 15. No abstract available.  
PMID: 27198275
  9. Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and potential Therapies?  
Califano R, Romanidou O, Mountzios G, Landi L, **Cappuzzo F**, Blackhall F.  
Drugs. 2016 May;76(8):831-40. doi: 10.1007/s40265-016-0578-z.  
PMID: 27129321
  10. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.  
Chatterjee M, Turner DC, Felip E, Lena H, **Cappuzzo F**, Horn L, Garon EB, Hui R, Arkenau H-T, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø.  
Ann Oncol. 2016 Jul;27(7):1291-8. doi: 10.1093/annonc/mdw174. Epub 2016 Apr 26.  
PMID: 27117531
  11. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.  
Klughammer B, Brugger W, **Cappuzzo F**, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS  
J Thorac Oncol. 2016 Apr;11(4):545-55.  
doi: 10.1016/j.jtho.2015.12.107. Epub 2016 Jan 8  
PMID: 26773740 Free Article
  12. Intracranial Efficacy of Crizotinib versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell lung cancer: Results From PROFILE 1014  
Solomon BJ, **Cappuzzo F**, Felip E, Blackhall FH, Costa DB, Kim D-W, Nakagawa K, Y-L Wu, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TSK  
J Clin Oncol. 2016 Mar 28. pii: JCO635888. [Epub ahead of print]  
PMID: 27022118
  13. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.  
Pérol M, Ciuleanu T-E, Arrieta O, Prabhaskar K, Syrigos KN, Goksel T, Park K, RD Kowalyszyn, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim J-H, Karaseva N, Yurasov S, Zimmermann A, Lee P, Cuyun Carter G, Reck M, **Cappuzzo F**, Garon EB.  
Lung Cancer. 2016 Mar;93:95-103. doi: 10.1016/j.lungcan.2016.01.007. Epub 2016 Jan 19.  
PMID: 26898621
  14. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.  
Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O.  
Ann Oncol. 2016 Feb;27(2):281-6. doi: 10.1093/annonc/mdv573. Epub 2015 Nov 23.  
PMID: 26598547
  15. Contribution of KRAS mutations and c.2369C>T (p. T790M) EGFR to acquired resistance to

- EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA  
Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, **Cappuzzo F**, Ardizzoni A, Scarpa A, Danesi R  
Oncotarget. 2016 Jan 20. doi: 10.18632/oncotarget.6957. [Epub ahead of print]  
PMID: 26799287 Free Article
16. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer  
Landi L, **Cappuzzo F**  
Expert Rev Clin Pharmacol. 2016;9(2):203-14. doi: 10.1586/17512433.2016.1122518. Epub 2015 Dec 16.  
PMID: 26582431
17. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.  
Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; GIM Study Group.  
JAMA. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291.  
PMID: 26720025
18. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers  
Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Ali G, D'Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, Cappuzzo F, Croce CM  
Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16.  
PMID: 26627242 Free PMC Article
19. Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.  
Minuti G, D'Incecco A, **Cappuzzo F**.  
Drugs Aging. 2015 Nov;32(11):907-16. doi: 10.1007/s40266-015-0305-6. Review.  
PMID: 26446154
20. Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.  
Osarogiagbon RU, **Cappuzzo F**, Ciuleanu T, Leon L, Klughammer B.  
Transl Lung Cancer Res. 2015 Aug;4(4):465-74. doi: 10.3978/j.issn.2218-6751.2015.07.17.  
PMID: 26380188 Free PMC Article
21. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.  
Barni S, Maiello E, Di Maio M, Ardizzoni A, **Cappuzzo F**, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group.  
Lung Cancer. 2015 Aug 19. pii: S0169-5002(15)30029-5. doi:10.1016/j.lungcan.2015.08.005. [Epub ahead of print]  
PMID: 26314614  
Select item 26063687
22. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.  
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulas V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators.  
Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.  
PMID: 26156651

23. Experience with erlotinib in the treatment of non-small cell lung cancer.  
Landi L, **Cappuzzo F**.  
Ther Adv Respir Dis. 2015 Aug;9(4):146-63. doi: 10.1177/1753465815588053. Epub 2015 Jun 10. Review.  
PMID: 26063687  
Select item 25955492
24. Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.  
D'Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D'Incecco A, Landi L, Apuzzo T, Rossi E, Sani S, Stassi G, **Cappuzzo F**.  
PLoS One. 2015 May 8;10(5):e0125037. doi: 10.1371/journal.pone.0125037. eCollection 2015.  
PMID: 25955492 Free PMC Article  
Select item 25891174
25. Pembrolizumab for the treatment of non-small-cell lung cancer.  
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lucey JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.  
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.  
PMID: 25891174  
Select item 25877855
26. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.  
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators.  
Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.  
PMID: 25877855  
Select item 25818471
27. Onartuzumab in lung cancer: the fall of Icarus?  
Rolfo C, Van Der Steen N, Pauwels P, **Cappuzzo F**.  
Expert Rev Anticancer Ther. 2015 May;15(5):487-9. doi: 10.1586/14737140.2015.1031219. Epub 2015 Mar 30.  
PMID: 25818471  
Select item 25815459
28. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.  
Van Der Steen N, Pauwels P, Gil-Bazo I, Castañón E, Ræz L, **Cappuzzo F**, Rolfo C.  
Cancers (Basel). 2015 Mar 25;7(2):556-73. doi: 10.3390/cancers7020556. Review.  
PMID: 25815459 Free PMC Article  
Select item 25815293
29. Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer.  
Landi L, **Cappuzzo F**.  
Ann Transl Med. 2015 Mar;3(3):32. doi: 10.3978/j.issn.2305-5839.2015.02.12. No abstract available.  
PMID: 25815293 Free PMC Article  
Select item 25806329
30. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.  
Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turtletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Arduini A,

- Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators.  
Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.  
PMID: 25740286  
Select item 25704439
31. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.  
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, **Cappuzzo F**, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.  
Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.  
PMID: 25704439  
Select item 25667280
32. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.  
Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, **Cappuzzo F**, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Millia JD, Thomas RK, Gautschi O.  
J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. Epub 2015 Feb 9.  
PMID: 25667280  
Select item 25576294
33. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.  
**Cappuzzo F**, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.  
Lung Cancer. 2015 Feb;87(2):89-95. doi: 10.1016/j.lungcan.2014.12.010. Epub 2014 Dec 18.  
PMID: 25576294 Free Article  
Select item 25527415
34. Nit-picking around second line in EGFRwt NSCLC: just an academic effort.  
Landi L, **Cappuzzo F**.  
Ann Oncol. 2015 Mar;26(3):448-50. doi: 10.1093/annonc/mdu575. Epub 2014 Dec No abstract available.  
PMID: 25527415  
Select item 25514804
35. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.  
**Cappuzzo F**, Finocchiaro G, Grossi F, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A.  
J Thorac Oncol. 2015 Apr;10(4):665-72. doi: 10.1097/JTO.0000000000000442.  
PMID: 25514804  
Select item 25511614
36. Targeting MET in NSCLC: looking for a needle in a haystack.  
Landi L, **Cappuzzo F**.  
Transl Lung Cancer Res. 2014 Dec;3(6):389-91. doi: 10.3978/j.issn.2218-6751.2014.11.05. No abstract available.  
PMID: 25806329 Free PMC Article  
Select item 25740286
37. The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?  
Passiglia F, Van Der Steen N, Raetz L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, **Cappuzzo F**, Rolfo C.  
Curr Drug Targets. 2014;15(14):1284-92. Review.  
PMID: 25511614  
Select item 25505694



38. Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.  
Stasi I, **Cappuzzo F**.  
Transl Respir Med. 2014 Jan 6;2:2. doi: 10.1186/2213-0802-2-2. eCollection 2014.  
PMID: 25505694 Free PMC Article  
Select item 25470694
39. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.  
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, **Cappuzzo F**, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators.  
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.  
PMID: 25470694 Free Article  
Select item 25349974
40. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.  
D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, **Cappuzzo F**.  
Br J Cancer. 2015 Jan 6;112(1):95-102. doi: 10.1038/bjc.2014.555. Epub 2014 Oct 28.  
PMID: 25349974  
Select item 25301075
41. Management of NSCLC: focus on crizotinib.  
Landi L, **Cappuzzo F**.  
Expert Opin Pharmacother. 2014 Dec;15(17):2587-97. doi:10.1517/14656566.2014.970174.  
Epub 2014 Oct 10. Review.  
PMID: 25301075
42. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.  
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, **Cappuzzo F**.  
Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.clc.2014.07.002. Epub 2014 Aug 16.  
PMID: 25242668  
Select item 25219817
43. Pharmacotherapy targeting the EGFR oncogene in NSCLC.  
Landi L, **Cappuzzo F**.  
Expert Opin Pharmacother. 2014 Nov;15(16):2293-305. doi: 10.1517/14656566.2014.957179.  
Epub 2014 Sep 13. Review.  
PMID: 25219817  
Select item 25139550
44. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.  
Novello S, Besse B, Felip E, Barlesi F, Mazieres J, Zalcman G, von Pawel J, Reck M, **Cappuzzo F**, Ferry D, Carcereny E, Santoro A, Garcia-Ribas I, Scagliotti G, Soria JC.  
Ann Oncol. 2014 Nov;25(11):2156-62. doi: 10.1093/annonc/mdu384. Epub 2014 Aug 19.  
PMID: 25139550  
Select item 25101329
45. Ceritinib for the treatment of non-small cell lung cancer.  
Landi L, **Cappuzzo F**.  
Drugs Today (Barc). 2014 Jul;50(7):465-73. doi: 10.1358/dot.2014.50.7.2133568. Review.  
PMID: 25101329  
Select item 25087901
46. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.  
Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, **Cappuzzo F**, Marchetti A, Crinò L.  
Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.clc.2014.06.004. Epub 2014 Jun 24.  
No abstract available.

- PMID: 25087901  
Select item 25052756
47. HER2 in solid tumors: more than 10 years under the microscope; where are we now?  
Martin V, **Cappuzzo F**, Mazzucchelli L, Frattini M.  
Future Oncol. 2014 Jun;10(8):1469-86. doi: 10.2217/fon.14.19. Review.  
PMID: 25052756  
Select item 25011934
48. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.  
Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, **Cappuzzo F**, Cervantes A, Frattini M, Fountzilias G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.  
Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.  
PMID: 25011934  
Select item 24933332
49. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.  
Garon EB, Ciuleanu TE, Arrieta O, Prabhaskar K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, **Cappuzzo F**, Alexandris E, Sashegyi A, Yurasov S, Pérol M.  
Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.  
PMID: 24933332  
Select item 24925809
50. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.  
de Marinis F, Ardizzoni A, Fontanini G, Grossi F, **Cappuzzo F**, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE Study Team.  
Clin Lung Cancer. 2014 Sep;15(5):338-45.e1. doi: 10.1016/j.clcc.2014.04.004. Epub 2014 May 14.  
PMID: 24925809  
Select item 24903964
51. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.  
Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, **Cappuzzo F**, Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; LIFE study team.  
J Cancer Res Clin Oncol. 2014 Oct;140(10):1783-93. doi: 10.1007/s00432-014-1715-2. Epub 2014 Jun 6.  
PMID: 24903964  
Select item 24885803
52. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.  
Ali G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, **Cappuzzo F**, Melfi F, Lucchi M, Mussi A, Fontanini G.  
Arch Pathol Lab Med. 2014 Nov;138(11):1449-58. doi: 10.5858/arpa.2013-0388-OA. Epub 2014 Jun 2.  
PMID: 24885803  
Select item 24745764
53. Protein kinase inhibitors to treat non-small-cell lung cancer.  
Minuti G, D'Incecco A, Landi L, **Cappuzzo F**.  
Expert Opin Pharmacother. 2014 Jun;15(9):1203-13. doi: 10.1517/14656566.2014.909412. Epub 2014 Apr 19. Review.  
PMID: 24745764  
Select item 24714591

54. Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.  
Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; "FOLLOW-UP" Study Group.  
PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014.  
PMID: 24714591 Free PMC Article  
Select item 24670920
55. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.  
Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidel D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly CM, **Cappuzzo F**, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK.  
Nat Commun. 2014 Mar 27;5:3518. doi: 10.1038/ncomms4518.  
PMID: 24670920 Free PMC Article  
Select item 24648382
56. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.  
Proietti A, Ali G, Pelliccioni S, Lupi C, Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, **Cappuzzo F**, Miccoli M, Fontanini G.  
Cancer Cytopathol. 2014 Jun;122(6):445-53. doi: 10.1002/cncy.21418. Epub 2014 Mar 19.  
PMID: 24648382  
Select item 24503111
57. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.  
**Cappuzzo F**, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S, Barbara C, Fontanini G, Crinò L, Blandino G.  
Clin Colorectal Cancer. 2014 Mar;13(1):37-45.e4. doi: 10.1016/j.clcc.2013.11.006. Epub 2013 Nov 14.  
PMID: 24503111  
Select item 24486058
58. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.  
Gridelli C, de Marinis F, **Cappuzzo F**, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.  
Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.clcc.2013.12.002. Epub 2013 Dec 27. Review.  
PMID: 24486058  
Select item 24174329
59. A genomics-based classification of human lung tumors.  
Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM).  
Sci Transl Med. 2013 Oct 30;5(209):209ra153. doi: 10.1126/scitranslmed.3006802.  
PMID: 24174329 Free PMC Article  
Select item 24134423
60. HER2 and lung cancer.  
Landi L, **Cappuzzo F**.  
Expert Rev Anticancer Ther. 2013 Oct;13(10):1219-28. doi: 10.1586/14737140.2013.846830.  
Review.  
PMID: 24134423  
Select item 24094287
61. Strategies for improving outcomes in NSCLC: a look to the future.  
Stahel R, Peters S, Baas P, Brambilla E, **Cappuzzo F**, De Ruyscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA.  
Lung Cancer. 2013 Dec;82(3):375-82. doi: 10.1016/j.lungcan.2013.08.025. Epub 2013 Sep 8.  
Review.  
PMID: 24094287 Free Article

62. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.  
Mazières J, Brugger W, **Cappuzzo F**, Middel P, Frosch A, Bara I, Klingelschmitt G, Klughammer B.  
Lung Cancer. 2013 Nov;82(2):231-7. doi: 10.1016/j.lungcan.2013.07.016. Epub 2013 Aug 7.  
PMID: 23972450 Free Article  
Select item 23930754
63. Targeted therapy for NSCLC with driver mutations.  
Minuti G, D'Incecco A, **Cappuzzo F**.  
Expert Opin Biol Ther. 2013 Oct;13(10):1401-12. doi: 10.1517/14712598.2013.827657. Epub 2013 Aug 10. Review.  
PMID: 23930754  
Select item 23820752
64. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features.  
Capodanno A, Boldrini L, Proietti A, Ali G, Pelliccioni S, Niccoli C, D'Incecco A, **Cappuzzo F**, Chella A, Lucchi M, Mussi A, Fontanini G.  
Int J Oncol. 2013 Sep;43(3):765-74. doi: 10.3892/ijo.2013.2003. Epub 2013 Jul 2.  
PMID: 23820752  
Select item 23647298
65. Rare mutations in non-small-cell lung cancer.  
D'Arcangelo M, D'Incecco A, **Cappuzzo F**.  
Future Oncol. 2013 May;9(5):699-711. doi: 10.2217/fo.13.16. Review.  
PMID: 23647298  
Select item 23617344
66. Erlotinib in the first-line treatment of non-small-cell lung cancer.  
D'Arcangelo M, **Cappuzzo F**.  
Expert Rev Anticancer Ther. 2013 May;13(5):523-33. doi: 10.1586/era.13.23. Review.  
PMID: 23617344  
Select item 23493885
67. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.  
D'Arcangelo M, **Cappuzzo F**.  
Biologics. 2013;7:61-8. doi: 10.2147/BTT.S28908. Epub 2013 Mar 3.  
PMID: 23493885 Free PMC Article  
Select item 23385860
68. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.  
Landi L, Minuti G, D'Incecco A, **Cappuzzo F**.  
Curr Opin Oncol. 2013 Mar;25(2):130-6. doi: 10.1097/CCO.0b013e32835daf37. Review.  
PMID: 23385860  
Select item 23370315
69. Epidermal growth factor receptor inhibition in lung cancer: status 2012.  
Hirsch FR, Jänne PA, Eberhardt WE, **Cappuzzo F**, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS.  
J Thorac Oncol. 2013 Mar;8(3):373-84. doi: 10.1097/JTO.0b013e31827ed0ff. Review.  
PMID: 23370315  
Select item 25806203
70. Irreversible EGFR-TKIs: dreaming perfection.  
Landi L, **Cappuzzo F**.  
Transl Lung Cancer Res. 2013 Feb;2(1):40-9. doi: 10.3978/j.issn.2218-6751.2012.12.05. Review.  
PMID: 25806203 Free PMC Article  
Select item 23348520
71. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.  
Martin V, Landi L, Molinari F, Fountzilias G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeris KT, Mazzucchelli L, Frattini M, **Cappuzzo F**.  
Br J Cancer. 2013 Feb 19;108(3):668-75. doi: 10.1038/bjc.2013.4. Epub 2013 Jan 24.

- PMID: 23348520 Free PMC Article  
Select item 22941188
72. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, **Cappuzzo F**, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sängler J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. *Nat Genet.* 2012 Oct;44(10):1104-10. doi: 10.1038/ng.2396. Epub 2012 Sep 2. PMID: 22941188  
Select item 22928785
73. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, **Cappuzzo F**, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R. *BJU Int.* 2013 Jan;111(1):44-52. doi: 10.1111/j.1464-410X.2012.11404.x. Epub 2012 Aug 29. PMID: 22928785  
Select item 22919003
74. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, **Cappuzzo F**, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC. *Clin Cancer Res.* 2012 Sep 1;18(17):4570-9. doi: 10.1158/1078-0432.CCR-12-0550. Epub 2012 Aug 23. PMID: 22919003 Free PMC Article  
Select item 22850551
75. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Minuti G, **Cappuzzo F**, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czarotoryska-Arlukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczyńska-Kłoda M, Tempieńska-Szałach A, Rossi E, Varella-Garcia M. *Br J Cancer.* 2012 Aug 21;107(5):793-9. doi: 10.1038/bjc.2012.335. Epub 2012 Jul 31. PMID: 22850551 Free PMC Article  
Select item 22833835
76. Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference? Landi L, **Cappuzzo F**. *J Thorac Dis.* 2012 Apr 1;4(2):226-8. doi: 10.3978/j.issn.2072-1439.2012.03.14. No abstract available. PMID: 22833835 Free PMC Article  
Select item 22767317
77. First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study. Tibaldi C, Camerini A, D'Incecco A, Vasile E, Fabbri A, Amoroso D, **Cappuzzo F**. *J Cancer Res Clin Oncol.* 2012 Dec;138(12):2003-8. doi: 10.1007/s00432-012-1280-5. Epub 2012 Jul 6. PMID: 22767317  
Select item 22712795
78. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Califano R, Landi L, **Cappuzzo F**. *Drugs.* 2012 Jun 19;72 Suppl 1:28-36. doi: 10.2165/1163012-S0-000000000-00000. Review.

- PMID: 22712795 Select item 22712791
79. Management of non-small cell lung cancer: focus on erlotinib. Foreword.  
**Cappuzzo F.**  
Drugs. 2012 Jun 19;72 Suppl 1:1-2. doi: 10.2165/1163029-S0-000000000-00000. No abstract available.  
PMID: 22712791  
Select item 25806176
80. EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMATION.  
Landi L, **Cappuzzo F.**  
Transl Lung Cancer Res. 2012 Jun;1(2):160-2. doi: 10.3978/j.issn.2218-6751.2012.06.05. No abstract available.  
PMID: 25806176 Free PMC Article  
Select item 22307009
81. p95HER2 truncated form in resected non-small cell lung cancer.  
**Cappuzzo F**, Cho YG, Sacconi A, Ali G, Siclari O, Incarbone M, Destro A, Terracciano L, Fontanini G, Marchetti A, Roncalli M, Varella-Garcia M.  
J Thorac Oncol. 2012 Mar;7(3):520-7. doi: 10.1097/JTO.0b013e318249e13f. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.  
PMID: 22307009
82. Emerging drugs for small cell lung cancer--an update.  
Metro G, Duranti S, Fischer MJ, **Cappuzzo F**, Crinò L.  
Expert Opin Emerg Drugs. 2012 Mar;17(1):31-6. doi: 10.1517/14728214.2012.656588. Epub 2012 Jan 31. Review.  
PMID: 22288522  
Select item 22266040
83. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.  
Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, **Cappuzzo F**, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R.  
Lung Cancer. 2012 Jun;76(3):269-79. doi: 10.1016/j.lungcan.2011.12.011. Epub 2012 Jan 21. Review.  
PMID: 22266040  
Select item 22130903
84. K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value.  
D'Arcangelo M, **Cappuzzo F.**  
ISRN Mol Biol. 2012 May 14;2012:837306. doi: 10.5402/2012/837306. eCollection 2012. Review. PMID: 27398239 Free PMC Article
85. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.  
Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, Frattini M, Torri V, **Cappuzzo F**, Vander Borgh S, Martin V, Skokan M, Santoro A, Gambacorta M, Tejpar S, Varella-Garcia M, Siena S.  
J Clin Pathol. 2012 Mar;65(3):218-23. doi: 10.1136/jclinpath-2011-200353. Epub 2011 Nov 30. Erratum in: J Clin Pathol. 2012 Jul;65(7):674.  
PMID: 22130903 Free Article  
Select item 22119437
86. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.  
Soria JC, Mok TS, **Cappuzzo F**, Jänne PA.  
Cancer Treat Rev. 2012 Aug;38(5):416-30. doi: 10.1016/j.ctrv.2011.10.003. Epub 2011 Nov 25. Review.  
PMID: 22119437  
Select item 22042954
87. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

- Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nicolis M, **Cappuzzo F**, Magnani M.  
J Clin Oncol. 2011 Dec 20;29(36):4789-95. doi: 10.1200/JCO.2011.36.7706. Epub 2011 Oct 31.  
PMID: 22042954 Free Article  
Select item 22039281
88. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.  
Gately K, O'Flaherty J, **Cappuzzo F**, Pirker R, Kerr K, O'Byrne K.  
J Clin Pathol. 2012 Jan;65(1):1-7. doi: 10.1136/jclinpath-2011-200275. Epub 2011 Oct 29.  
Review.  
PMID: 22039281  
Select item 21969500
89. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.  
Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whitton R, Ward C, Mayne K, Trunzer K, **Cappuzzo F**.  
J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3.  
Erratum in: J Clin Oncol. 2011 Dec 10;29(35):4725.  
PMID: 21969500 Free Article  
Select item 21905963
90. Gefitinib for non-small-cell lung cancer treatment.  
D'Incecco A, **Cappuzzo F**.  
Expert Opin Drug Saf. 2011 Nov;10(6):987-96. doi: 10.1517/14740338.2011.617738. Epub 2011 Sep 12. Review.  
PMID: 21905963  
Select item 21900593
91. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.  
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, **Cappuzzo F**, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Phillips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA.  
Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.  
PMID: 21900593 Free PMC Article  
Select item 21878894
92. Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR.  
Landi L, **Cappuzzo F**.  
Nat Rev Clin Oncol. 2011 Aug 30;8(10):571-3. doi: 10.1038/nrclinonc.2011.135. No abstract available.  
PMID: 21878894  
Select item 21727198
93. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.  
Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus PE, Sorensen JB, Felip E; Panel members.  
Ann Oncol. 2011 Sep;22(9):1973-80. doi: 10.1093/annonc/mdr313. Epub 2011 Jul 4.  
PMID: 21727198 Free Article  
Select item 21652582
94. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.  
Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, **Cappuzzo F**, Ardizzoni A, Peters GJ.  
Ann Oncol. 2012 Mar;23(3):670-7. doi: 10.1093/annonc/mdr280. Epub 2011 Jun 7.  
PMID: 21652582 Free Article  
Select item 21610154
95. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.  
Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, Gopalakrishna P, **Cappuzzo**

- F; SATURN Investigators.  
Ann Oncol. 2012 Feb;23(2):388-94. doi: 10.1093/annonc/mdr125. Epub 2011 May 24.  
PMID: 21610154 Free Article  
Select item 21536661
96. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.  
Felip E, Gridelli C, Baas P, Rosell R, Stahel R; Panel Members.  
Ann Oncol. 2011 Jul;22(7):1507-19. doi: 10.1093/annonc/mdr150. Epub 2011 May 2.  
PMID: 21536661 Free Article  
Select item 21292645
97. Is FISH floating or still swimming in the lung cancer ocean?  
**Cappuzzo F**, Camidge DR, Varella-Garcia M.  
Ann Oncol. 2011 Mar;22(3):493-9. doi: 10.1093/annonc/mdq752. Epub 2011 Feb 3. No abstract available. Erratum in: Ann Oncol. 2011 Jun;22(6):1467.  
PMID: 21292645 Free Article  
Select item 21252721
98. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.  
Tibaldi C, Giovannetti E, Vasile E, Boldrini L, Gallegos-Ruiz MI, Bernardini I, Incensati R, Danesi R, **Cappuzzo F**, Peters GJ, Fontanini G.  
J Thorac Oncol. 2011 Feb;6(2):395-6. doi: 10.1097/JTO.0b013e3182059a6f. No abstract available.  
PMID: 21252721  
Select item 21216488
99. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.  
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, **Cappuzzo F**, Mok T.  
Lung Cancer. 2011 Apr;72(1):3-8. doi: 10.1016/j.lungcan.2010.12.009. Epub 2011 Jan 8.  
Review.  
PMID: 21216488  
Select item 21216486
100. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.  
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, **Cappuzzo F**, Mok T.  
Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8.  
Review.  
PMID: 21216486  
Select item 21160078
101. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.  
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, **Cappuzzo F**, Ligorio C, Damiani S, Hallek M, Beroukhi R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK.  
Sci Transl Med. 2010 Dec 15;2(62):62ra93. doi: 10.1126/scitranslmed.3001451. Erratum in: Sci Transl Med. 2011 Jan 19;3(66):66er2. Sci Transl Med. 2012 Apr 18;4(130):130er2.  
PMID: 21160078 Free PMC Article  
Select item 20943621
102. Consequences of targeted treatments for second-line therapy.  
De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, **Cappuzzo F**.  
Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Review.  
PMID: 20943621 Free Article



103. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.  
Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Douillard JY.  
Oncologist. 2010;15(10):1102-12. doi: 10.1634/theoncologist.2010-0322. Epub 2010 Oct 7.  
Review.  
PMID: 20930102 Free PMC Article  
Select item 20871269
104. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.  
Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, **Cappuzzo F**, Stahel R; European EGFR Workshop Group.  
J Thorac Oncol. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de.  
PMID: 20871269  
Select item 20619739
105. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.  
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, **Cappuzzo F**, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.  
Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.  
PMID: 20619739  
Select item 20493771
106. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.  
**Cappuzzo F**, Ciuleanu T, Stelmakh L, Cicenias S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators.  
Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.  
PMID: 20493771  
Select item 20443070
107. Impact of biomarkers on non-small cell lung cancer treatment.  
Toschi L, **Cappuzzo F**.  
Target Oncol. 2010 Mar;5(1):5-17. doi: 10.1007/s11523-010-0132-y. Epub 2010 May 5.  
Review.  
PMID: 20443070  
Select item 20163822
108. Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?  
Sterlacci W, **Cappuzzo F**, Savic S, Bubendorf L, Tzankov A.  
Hum Pathol. 2010 Apr;41(4):614-5; author reply 615-616. doi: 10.1016/j.humpath.2009.11.009. Epub 2010 Feb 16. No abstract available.  
PMID: 20163822  
Select item 20146583
109. Clinical implications of MET gene copy number in lung cancer.  
Toschi L, **Cappuzzo F**.  
Future Oncol. 2010 Feb;6(2):239-47. doi: 10.2217/fon.09.164. Review.  
PMID: 20146583  
Select item 20138388
110. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP).  
Stahel R, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazières J, **Cappuzzo F**, Früh M, Sorensen JB, Blackhall F, Taron M, Gridelli C, O'Byrne K, Rosell R.

- Lung Cancer. 2010 Apr;68(1):121-4. doi: 10.1016/j.lungcan.2010.01.010. No abstract available.  
PMID: 20138388  
Select item 19861557
111. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.  
Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, **Cappuzzo F**.  
J Clin Pathol. 2009 Nov;62(11):970-7. doi: 10.1136/jcp.2009.066548.  
PMID: 19861557 Free PMC Article  
Select item 19794967
112. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.  
Marchetti A, Milella M, Felicioni L, **Cappuzzo F**, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F.  
Neoplasia. 2009 Oct;11(10):1084-92.  
PMID: 19794967 Free PMC Article  
Select item 19786660
113. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.  
Leidner RS, Fu P, Clifford B, Hamdan A, Jin C, Eisenberg R, Boggon TJ, Skokan M, Franklin WA, **Cappuzzo F**, Hirsch FR, Varella-Garcia M, Halmos B.  
J Clin Oncol. 2009 Nov 20;27(33):5620-6. doi: 10.1200/JCO.2009.23.1431. Epub 2009 Sep 28.  
PMID: 19786660 Free PMC Article  
Select item 19767315
114. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.  
**Cappuzzo F**, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A.  
Ann Oncol. 2010 Mar;21(3):562-7. doi: 10.1093/annonc/mdp357. Epub 2009 Sep 18.  
PMID: 19767315 Free PMC Article  
Select item 19694501
115. Emerging drugs for small-cell lung cancer.  
Metro G, **Cappuzzo F**.  
Expert Opin Emerg Drugs. 2009 Dec;14(4):591-606. doi: 10.1517/14728210903206983. Review.  
PMID: 19694501  
Select item 19680294
116. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.  
Hirsch FR, Varella-Garcia M, **Cappuzzo F**.  
Oncogene. 2009 Aug;28 Suppl 1:S32-7. doi: 10.1038/onc.2009.199. Review.  
PMID: 19680294  
Select item 19549709
117. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.  
Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, **Cappuzzo F**, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V.  
Ann Oncol. 2009 Oct;20(10):1674-81.  
doi: 10.1093/annonc/mdp060. Epub 2009 Jun 23.  
PMID: 19549709 Free Article  
Select item 19520905
118. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial.  
Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, Passera E, Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Errico V, Inzirillo F, Bottoni E, Voulaz E, Alloisio M, Destro A, Roncalli M, Santoro A, Ravasi G; DANTE Study Group.

- Am J Respir Crit Care Med. 2009 Sep 1;180(5):445-53. doi: 10.1164/rccm.200901-0076OC. Epub 2009 Jun 11.  
PMID: 19520905  
Select item 19255323
119. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.  
**Cappuzzo F**, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M.  
J Clin Oncol. 2009 Apr 1;27(10):1667-74. doi: 10.1200/JCO.2008.19.1635. Epub 2009 Mar 2. PMID: 19255323 Free PMC Article  
Select item 19204574
120. MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.  
**Cappuzzo F**, Varella-Garcia M, Rossi E, Gajapathy S, Valente M, Drabkin H, Gemmill R.  
J Thorac Oncol. 2009 Apr;4(4):472-8. doi: 10.1097/JTO.0b013e31819a5767. PMID: 19204574 Free PMC Article  
Select item 20616908
121. Gemcitabine for the treatment of advanced nonsmall cell lung cancer.  
Toschi L, **Cappuzzo F**.  
Onco Targets Ther. 2009 Feb 18;2:209-17. PMID: 20616908 Free PMC Article  
Select item 18836087
122. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.  
**Cappuzzo F**, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M.  
Ann Oncol. 2009 Feb;20(2):298-304. doi: 10.1093/annonc/mdn635. Epub 2008 Oct 3.
123. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.  
Crinò L, **Cappuzzo F**, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M.  
J Clin Oncol. 2008 Sep 10;26(26):4253-60. doi: 10.1200/JCO.2007.15.0672. PMID: 18779612 Free Article  
Select item 18577988
124. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.  
**Cappuzzo F**, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA.  
Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24. PMID: 18577988 Free PMC Article  
Select item 18542071
125. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.  
Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, **Cappuzzo F**, Marangolo M, Torri V, Santoro A.  
Br J Cancer. 2008 Jul 8;99(1):51-6. doi: 10.1038/sj.bjc.6604442. Epub 2008 Jun 10. PMID: 18542071 Free PMC Article  
Select item 18486986
126. Primary pulmonary meningioma: report of a case and review of the literature.  
Incarbone M, Ceresoli GL, Di Tommaso L, **Cappuzzo F**, Inzirillo F, Infante M, Alloisio M.  
Lung Cancer. 2008 Dec;62(3):401-7. doi: 10.1016/j.lungcan.2008.03.031. Epub 2008 May 19. PMID: 18486986  
Select item 18393776
127. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

- Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, **Cappuzzo F**.  
Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review.  
PMID: 18393776  
Select item 18367287
128. EGFR FISH versus mutation: different tests, different end-points.  
**Cappuzzo F**.  
Lung Cancer. 2008 May;60(2):160-5. doi: 10.1016/j.lungcan.2008.02.008. Epub 2008 Mar 25.  
Review.  
PMID: 18367287  
Select item 18286536
129. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.  
Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, **Cappuzzo F**, Salamina S, Soto Parra HJ, Santoro A.  
Cancer. 2008 Apr 1;112(7):1555-61. doi: 10.1002/cncr.23337.  
PMID: 18286536 Free Article  
Select item 17974556
130. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.  
**Cappuzzo F**, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M.  
Ann Oncol. 2008 Apr;19(4):717-23. Epub 2007 Oct 31.  
PMID: 17974556 Free Article  
Select item 17936405
131. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial.  
Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E, Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Alloisio M, Incarbone M, Testori A, Destro A, **Cappuzzo F**, Roncalli M, Santoro A, Ravasi G; DANTE Study Group.  
Lung Cancer. 2008 Mar;59(3):355-63. Epub 2007 Oct 23.  
PMID: 17936405  
Select item 23489305
132. EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?  
Finocchiaro G, Toschi L, Garassino I, De Vincenzo F, Campagnoli E, Zucali P, Cavina R, Ceresoli GL, Santoro A, **Cappuzzo F**.  
Expert Opin Med Diagn. 2007 Oct;1(2):183-91. doi: 10.1517/17530059.1.2.183.  
PMID: 23489305  
Select item 17631569
133. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer.  
Toschi L, **Cappuzzo F**, Jänne PA.  
Ann Oncol. 2007 Jul;18 Suppl 9:ix150-5. Review. No abstract available.  
PMID: 17631569 Free Article  
Select item 17764849
134. Assessment of tumor response in malignant pleural mesothelioma.  
Ceresoli GL, Chiti A, Zucali PA, **Cappuzzo F**, De Vincenzo F, Cavina R, Rodari M, Poretti D, Lutman FR, Santoro A.  
Cancer Treat Rev. 2007 Oct;33(6):533-41. Epub 2007 Aug 30. Review.  
PMID: 17764849  
Select item 17538169
135. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.  
**Cappuzzo F**, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M.  
J Clin Oncol. 2007 Jun 1;25(16):2248-55.

- PMID: 17538169 Free Article  
Select item 20528311
136. Is gemcitabine cost effective in cancer treatment?  
Toschi L, Finocchiaro G, Ceresoli GL, Zucali PA, Cavina R, Garassino I, De Vincenzo F, Santoro A, **Cappuzzo F**.  
Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):239-49. doi:  
10.1586/14737167.7.3.239.  
PMID: 20528311  
Select item 17520577
137. 115.Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges.  
**Cappuzzo F**, Toschi L, Finocchiaro G, Ligorio C, Santoro A.  
Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S10-23. Review.  
PMID: 17520577  
Select item 17473658
138. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).  
**Cappuzzo F**, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Hirsch FR, Crino L, Varella-Garcia M.  
J Thorac Oncol. 2007 May;2(5):423-9. Erratum in: J Thorac Oncol. 2007 Jul;2(7):676. Ligorio, Claudio [corrected to Ligorio, Claudia].  
PMID: 17473658  
Select item 17463250
139. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.  
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, **Cappuzzo F**, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.  
Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.  
PMID: 17463250 Free Article  
Select item 17457222
140. Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer.  
**Cappuzzo F**.  
J Thorac Oncol. 2007 May;2(5 Suppl):S12-4. Review. No abstract available.  
PMID: 17457222  
Select item 17409995
141. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria.  
Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, **Cappuzzo F**, Vazquez M.  
J Thorac Oncol. 2006 Nov;1(9 Suppl):S13-9.  
PMID: 17409995  
Select item 17317677
142. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.  
Hirsch FR, Varella-Garcia M, **Cappuzzo F**, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr.  
Ann Oncol. 2007 Apr;18(4):752-60. Epub 2007 Feb 22.  
PMID: 17317677
143. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.  
Toschi L, **Cappuzzo F**.  
Oncologist. 2007 Feb;12(2):211-20. Review.  
PMID: 17296817 Free Article  
Similar articles

- Select item 17105366
144. Should every lung cancer patient be tested for EGFR mutation?  
**Cappuzzo F.**  
Expert Opin Ther Targets. 2006 Dec;10(6):789-91.  
PMID: 17105366  
Select item 16807461
145. Development of gemcitabine in non-small cell lung cancer: the Italian contribution.  
Metro G, **Cappuzzo F**, Finocchiaro G, Toschi L, Crinò L.  
Ann Oncol. 2006 May;17 Suppl 5:v37-46. Review.  
PMID: 16807461 Free Article  
Select item 16775247
146. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.  
**Cappuzzo F**, Bemis L, Varella-Garcia M.  
N Engl J Med. 2006 Jun 15;354(24):2619-21. No abstract available.  
PMID: 16775247 Free Article  
Select item 16707605
147. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.  
Dziadziuszko R, Witta SE, **Cappuzzo F**, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA Jr, Varella-Garcia M, Danenberg KD, Hirsch FR.  
Clin Cancer Res. 2006 May 15;12(10):3078-84.  
PMID: 16707605 Free Article  
Select item 16630670
148. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.  
**Cappuzzo F**, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L, Crinò L.  
Lung Cancer. 2006 Jun;52(3):319-25. Epub 2006 Apr 19.  
PMID: 16630670  
Select item 16608980
149. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance.  
Metro G, Finocchiaro G, **Cappuzzo F**.  
Ann Oncol. 2006 Mar;17 Suppl 2:ii42-45. Review. No abstract available.  
PMID: 16608980 Free Article  
Select item 16600976
150. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.  
**Cappuzzo F**, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR.  
Ann Oncol. 2006 Jul;17(7):1120-7. Epub 2006 Apr 6.  
PMID: 16600976 Free Article  
Select item 16555971
151. Role of gemcitabine in cancer therapy.  
Toschi L, Finocchiaro G, Bartolini S, Gioia V, **Cappuzzo F**.  
Future Oncol. 2005 Feb;1(1):7-17. Review.  
PMID: 16555971  
Select item 16531062
152. Clinical experience with gefitinib: an update.  
**Cappuzzo F**, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L.  
Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45. Epub 2006 Mar 13. Review.  
PMID: 16531062  
Select item 16288303
153. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.

- Cappuzzo F**, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA Jr, Hirsch FR, Varella-Garcia M. Br J Cancer. 2005 Dec 12;93(12):1334-40. PMID: 16288303 Free PMC Article  
Select item 16267615
154. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Venturini M, Bighin C, Monfardini S, **Cappuzzo F**, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L. Breast Cancer Res Treat. 2006 Jan;95(1):45-53. PMID: 16267615  
Select item 16131043
155. Perspectives on salvage therapy for non-small-cell lung cancer. **Cappuzzo F**, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G, Crinò L. Oncology (Williston Park). 2005 Jul;19(8):989-95; discussion 995-6, 999, 1003-4, passim. Review. PMID: 16131043 Free Article  
Select item 16051952
156. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. **Cappuzzo F**, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. J Clin Oncol. 2005 Aug 1;23(22):5007-18. PMID: 16051952 Free Article  
Select item 15956971
157. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. **Cappuzzo F**, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, Lorusso V, Barbieri F, Castaldini L, Crucitta E, Marini L, Bartolini S, Scagliotti GV, Crinò L. Br J Cancer. 2005 Jul 11;93(1):29-34. PMID: 15956971 Free PMC Article  
Select item 15956643
158. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? **Cappuzzo F**. J Natl Cancer Inst. 2005 Jun 15;97(12):868-9. No abstract available. PMID: 15956643 Free Article  
Select item 15886315
159. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, **Cappuzzo F**, Vazquez M. J Clin Oncol. 2005 May 10;23(14):3279-87. Review. PMID: 15886315  
Select item 15870435
160. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. **Cappuzzo F**, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. J Natl Cancer Inst. 2005 May 4;97(9):643-55. PMID: 15870435 Free Article  
Select item 15447984
161. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, **Cappuzzo F**, Crinò L, Tonato M, Villa E.

- Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6006-12.  
PMID: 15447984 Free Article  
Select item 15339057
162. Induction therapy for early-stage non-small-cell lung cancer.  
**Cappuzzo F**, Bartolini S, Calandri C, Crinò L.  
Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):32-7. Review.
163. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.  
**Cappuzzo F**, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L.  
J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41.  
PMID: 15292385 Free Article  
Select item 15205197
164. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.  
Ceresoli GL, **Cappuzzo F**, Gregorc V, Bartolini S, Crinò L, Villa E.  
Ann Oncol. 2004 Jul;15(7):1042-7.  
PMID: 15205197 Free Article  
Select item 14710211
165. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).  
**Cappuzzo F**, Bartolini S, Ceresoli GL, Tamperi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crinò L.  
Br J Cancer. 2004 Jan 12;90(1):82-6.  
PMID: 14710211 Free PMC Article  
Select item 14710202
166. Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.  
**Cappuzzo F**, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crinò L, Conte PF.  
Br J Cancer. 2004 Jan 12;90(1):31-5.  
PMID: 14710202 Free PMC Article  
Select item 14644524
167. Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.  
**Cappuzzo F**, De Marinis F, Nelli F, Calandri C, Maestri A, Benedetti G, Migliorino MR, Cortesi E, Rastelli F, Martelli O, Andruccetti M, Bartolini S, Crinò L.  
Lung Cancer. 2003 Dec;42(3):355-61.  
PMID: 14644524  
Select item 14610920
168. Emerging drugs for non-small cell lung cancer.  
**Cappuzzo F**, Bartolini S, Crinò L.  
Expert Opin Emerg Drugs. 2003 May;8(1):179-92. Review.  
PMID: 14610920  
Select item 12871787
169. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).  
**Cappuzzo F**, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, Calandri C, Bartolini S, Santoro A, Crinò L.  
Lung Cancer. 2003 Aug;41(2):227-31.  
PMID: 12871787  
Select item 12865910
170. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.  
**Cappuzzo F**, Calandri C, Bartolini S, Crinò L.  
Br J Cancer. 2003 Jul 21;89(2):246-7.  
PMID: 12865910 Free PMC Article  
Select item 12860941



171. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.  
**Cappuzzo F**, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L.  
J Clin Oncol. 2003 Jul 15;21(14):2658-63.  
PMID: 12860941  
Select item 12833465
172. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.  
**Cappuzzo F**, Selvaggi G, Gregorc V, Mazzoni F, Betti M, Rita Migliorino M, Novello S, Maestri A, De Marinis F, Darwish S, De Angelis V, Nelli F, Bartolini S, Scagliotti GV, Tonato M, Crinò L.  
Cancer. 2003 Jul 1;98(1):128-34.  
PMID: 12833465 Free Article  
Select item 12415823
173. Medical treatment of brain metastases from lung cancer.  
**Cappuzzo F**.  
Suppl Tumori. 2002 Jul-Aug;1(4):S58-9. Review. No abstract available.  
PMID: 12415823  
Select item 12415810
174. New platinum derivatives in advanced non-small cell lung cancer.  
Crinò L, **Cappuzzo F**.  
Suppl Tumori. 2002 Jul-Aug;1(4):S24-5. Review. No abstract available.  
PMID: 12415810  
Select item 12094333
175. Present and future treatment of advanced non-small cell lung cancer.  
Crinò L, **Cappuzzo F**.  
Semin Oncol. 2002 Jun;29(3 Suppl 9):9-16. Review.  
PMID: 12094333  
Select item 12036414
176. Gemcitabine in non-small cell lung cancer.  
Crinò L, **Cappuzzo F**.  
Expert Opin Pharmacother. 2002 Jun;3(6):745-53. Review.  
PMID: 12036414  
Select item 11740993
177. Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings.  
Crinò L, **Cappuzzo F**.  
Lung Cancer. 2001 Dec;34 Suppl 3:S45-7. No abstract available.  
PMID: 11740993  
Select item 11556252
178. [Role of gemcitabine in the treatment of advanced non-small cell lung cancer: review of the main phase II and phase III trials].  
Crino L, **Cappuzzo F**.  
Anticancer Drugs. 2001 Jul;12 Suppl 3:S9-13. Review. French.  
PMID: 11556252  
Select item 10960939
179. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.  
**Cappuzzo F**, Rocha Lima CM, Sherman CA, Green MR.  
Oncology (Williston Park). 2000 Jul;14(7 Suppl 4):7-14. Review.  
PMID: 10960939 Free Article  
Select item 10875975
180. Medical treatment of brain metastases from solid tumours.  
**Cappuzzo F**, Mazzoni F, Maestri A, Di Stefano A, Calandri C, Crino L.  
Forum (Genova). 2000 Apr-Jun;10(2):137-48. Review.

- PMID: 10875975  
Select item 9263281
181. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study.  
Bozzetti F, Biganzoli L, Gavazzi C, **Cappuzzo F**, Carnaghi C, Buzzoni R, Dibartolomeo M, Baietta E.  
Nutrition. 1997 Jul-Aug;13(7-8):748-51.  
PMID: 9263281  
Select item 9214274
182. Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection.  
Bajetta E, **Cappuzzo F**.  
Ann Ital Chir. 1996 Nov-Dec;67(6):827-30. Italian.
183. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.  
Bajetta E, Di Leo A, Biganzoli L, Mariani L, **Cappuzzo F**, Di Bartolomeo M, Zilembo N, Artale S, Magnani E, Celio L, Buzzoni R, Carnaghi C.  
J Clin Oncol. 1996 Sep;14(9):2546-51.  
PMID: 8823334  
Select item 7478430
184. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.  
Noberasco C, Bajetta E, Zilembo N, Di Leo A, **Cappuzzo F**, Bartoli C, Bono A, Bichisao E.  
Oncology. 1995 Nov-Dec;52(6):454-7.  
PMID: 7478430  
Select item 7595715
185. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.  
Bajetta E, Colleoni M, Di Bartolomeo M, Buzzoni R, Bozzetti F, Doci R, Somma L, **Cappuzzo F**, Stampino CG, Guenzi A, et al.  
J Clin Oncol. 1995 Oct;13(10):2613-9.  
PMID: 7595715

#### Book Chapters

1. **Cappuzzo F**, Le Pechoux C, and Le Chevalier T. Small cell lung cancer. In: Oncologic Therapies, Editors Vokes/Golomb, Springer-Verlag, 620-631, 1998
2. **Cappuzzo F**, Zappalà A, and Le Chevalier T. Should all stage IV Non-Small Cell Lung Cancer be treated palliatively ? In :Medical Radiology. Diagnostic Imaging and Radiation Oncology. Editors P. Van Houtte, J. Klastersky, P. Rocmans. Progress and Perspectives in The Treatment of Lung Cancer, Springer-Verlag, 183-189, 1999
3. **Cappuzzo F**, Le Pechoux C, and Le Chevalier T. Small cell lung cancer. In: Oncologic Therapies, Editors Vokes/Golomb, Springer-Verlag, 407-414, 2002
4. **Cappuzzo F**, Bartolini S, Crino L. Targeted therapies for Non-Small Cell Lung Cancer (NSCLC). In: Focus on lung cancer, Nova publisher, 305-329, 2004
5. Finocchiaro G, Bartolini S, Cappuzzo F, Crino L. Tumori del polmone. In: Terapia molecolare in oncologia. Poletto Editore, 2005:182-200.
6. Bidoli P, Cortinovis D, **Cappuzzo F**, Pastorino U. Neoplasie del polmone. In: Medicina Oncologica by G. Bonadonna, G. Robustelli Della Cuna, P. Valagussa, Masson Editore, 2006
7. **Cappuzzo F**. Guide to Targeted Therapies: EGFR mutations in NSCLC. Springer 2014
8. **Cappuzzo F**. Guide to targeted therapies: treatment resistance in lung cancer. Springer 2015

